Metabolomics in cancer: a bench-to-bedside intersection

Crit Rev Oncol Hematol. 2012 Oct;84(1):1-7. doi: 10.1016/j.critrevonc.2012.02.009. Epub 2012 Mar 18.

Abstract

The field of oncology is a rapidly evolving science mostly due to extensive basic, translational and clinical research which have provided more insights into the tumor biology and set grounds for the development of new therapies. Metabolomics is the upcoming new science in the omics field with the potential to further increment our knowledge of cancer biology. In this review we intend to explore the potential role of metabolomics in understanding cancer process, improving cancer staging, refining tumor characterization and in the search for predictive biomarkers of response and toxicity.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor
  • Drug Discovery
  • Genomics
  • Genotype
  • Humans
  • Metabolomics*
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy
  • Phenotype
  • Prognosis
  • Translational Research, Biomedical

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor